Skip to main content

Many of the drug classes which are included in the prior authorization program are reviewed each fiscal year.  These reports include detailed statistics on utilization, prior authorization, market share, new products, and other notable events for the category during the previous year.  These reports were not included on a DUR Board agenda and are in addition to the utilization reports included with the DUR Board packets.

FY 2011

Albuterol Inhalers
Amitiza
Antiemetics
Anti-migraine
Anxiolytics
Bladder Control
Brovana
Byetta_Victoza
Elidel_Protopic
Fibric Acid Derivatives
Fibromyalgia
Glaucoma
Glumetza and Fortamet
Insomnia
Lamisil
Muscle Relaxants
Ocular Allergy
Osteoporosis
Otic Antibiotics
Plavix and Effient
PPIs
Qualaquin
Smoking Cessation
Stimulants
Symlin
Topical Antifungals
Xolair
Xopenex

Last Modified on Nov 10, 2020
Back to Top
Back to top

Oklahoma Health Care Authority

4345 N Lincoln Blvd

Oklahoma City, OK 73105

Contact Us

The Oklahoma Health Care Authority collects the personally identifiable data submitted and received in regard to applications for services, renewals, appeals, provision of health care and processing of claims. This data is treated as confidential and is stored securely in accordance with applicable law and regulations. OHCA may share this personally identifiable data with its authorized business associates, government agencies with jurisdiction over the OHCA, or as otherwise required or permitted by applicable law.